What is the gap between generic drugs and original drugs?

Introduction

In the global pharmaceutical market, competition between generic drugs (GDs) and original medicines (OMs) has always been the focus of industry attention. With the expiration of patents and advances in pharmaceutical technology, generics have not only gained a price advantage but have also pushed the industry forward in some technical details. This article discusses the following aspects:

What is a generic drug?

Generic drugs are drugs produced by other pharmaceutical companies based on the same or similar active ingredients, dosage forms, and doses after the patents of the originator drugs have expired. Generic drugs are basically the same as the originator drugs in terms of efficacy, quality, dosage forms, safety, and indications, but they usually have a significant advantage in terms of research and development, production costs, and prices. While originator drugs invest huge amounts of capital and time in the R&D phase, generic drugs rely more on mature technology and large-scale production to reduce costs so that patients can enjoy drugs with the same efficacy at a lower price.

In addition, the lower R&D risk of generic drugs and the fierce competition in the market have also contributed to some extent to the advancement of pharmaceutical technology through the continuous improvement of processes and optimization of drug formulations by various pharmaceutical companies. As shown in some drug cases, the molecular formula of azithromycin based on erythromycin has been improved, reflecting that generic drugs have inherited the advantages of the original drugs while also showing their own innovation potential.

History and Global Status of Generic Drugs

Historical Review

The history of generic drug development can be traced back to the mid-20th century. With the gradual improvement of the patent protection system and the popularization of globalized pharmaceutical technology, the expiration of patents on original drugs provided opportunities for other companies to enter the market. After patents expired, governments and health authorities encouraged the promotion and use of generic drugs to reduce healthcare costs. Today, generics have become an important part of the pharmaceutical market in various countries.

Market share data by country

USA: The United States is one of the largest generic drug markets in the world. According to statistics, despite the fact that original drugs have a greater advantage in R&D investment and marketing, about 90% of prescription drugs in the U.S. market are generic in terms of sales volume and quantity. This high percentage not only effectively reduces the cost of drugs for patients but also promotes the standardization of pharmaceutical processes and large-scale production.

In recent years, the Chinese government has vigorously promoted the approval and use of generic drugs in an effort to realize the guarantee of drug quality and efficacy. Currently, the proportion of generic drugs in the Chinese market has reached 70%~80%, and in some therapeutic areas, the efficacy of generic drugs is comparable to that of originator drugs, which is widely recognized.

While promoting generic drugs, countries also continue to improve the regulatory mechanism to ensure that generic drugs are equivalent to original drugs in terms of safety and efficacy and to promote fair competition in the pharmaceutical market.

Patents and Generic Disputes of Original Drugs

The Importance of Patents for Original Research Drugs

The original drug has gone through a lot of clinical trials and R&D investment before it is launched on the market. Patent protection not only protects the R&D results of innovative pharmaceutical companies, but also provides them with a period of market exclusivity, allowing them to recoup huge R&D expenses. However, once the patent expires, other pharmaceutical companies can produce generic versions, creating fierce competition in the marketplace.

Generic litigation cases

Litigation between generic companies and originator companies is common in patent litigation. One notable case is the patent litigation between Ranbaxy Laboratories, one of India's largest generic drug manufacturers, and various originator companies for alleged infringement of originator patents. In these cases, courts often have to strike a balance between protecting innovation and promoting access to medicines, both by protecting the intellectual property rights of the originator company and by ensuring that generic medicines can be brought to market at lower prices for the benefit of patients.

Such disputes not only reflect the vast differences in marketing strategies and R&D investments between the two drugs but also highlight the complex balancing act between intellectual property rights and the public interest in the global pharmaceutical market. Through these litigation cases, we can see that although generic drugs are inexpensive and have a high market share, they still have certain limitations in R&D and innovation, while originator drugs ensure the uniqueness of their innovations and market returns through the patent system.

Specific differences between generics and originator products

R&D and production costs

Originator drugs require a lot of basic research, clinical trials, and safety testing at the R&D stage, costing huge sums of money and a long period of time, whereas generic drugs are based on the original formula and are quickly put into production after the patent expires, greatly reducing R&D costs and time. This is also an important reason why the price of generic drugs is generally lower than that of originator drugs.

Formulation and process improvement

Although generic drugs are basically the same as originator drugs in terms of formulation, pharmaceutical companies can optimize certain processes during the actual production process. For example, azithromycin is a new type of molecule based on the molecular formula of erythromycin that has been improved to enhance the stability and tolerance of the drug. This phenomenon of innovation in imitation proves that generics also play a positive role in promoting the advancement of pharmaceutical technology.

Marketing and regulation

Due to their technological leadership and patent protection, originator drugs tend to have higher market awareness and brand equity in the early stages of marketing, while generic drugs rely more on price advantage and mass production to gain market share. Governments emphasize that generic drugs must meet the same standards of efficacy and safety as originator drugs in terms of drug regulation, so both originator and generic drugs must go through a rigorous approval process before they can be marketed. 

Quality and efficacy

In terms of drug quality, generic drugs are internationally required to have the same active ingredients, dosage forms, and doses as the originator drug, so in theory there should be no significant difference in efficacy between the two. However, due to possible differences in production processes and equipment, some generic drugs require continuous technical improvements in microprocesses to ensure a high degree of consistency with the originator drug.

Comparison of Pharmaceutical Production Processes and Equipment

Whether it is an original drug or a generic drug, its production process cannot be separated from the support of efficient and precise pharmaceutical production process and equipment. In this process, the role of pharmaceutical production line cannot be underestimated. Below, we will discuss the differences between the two in terms of production processes and equipment.

Pharmaceutical manufacturing processes

Dosing and mixing: 

The initial formulation of a drug, whether originator or generic, requires strict control of the quality and proportion of raw materials. Modern pharmaceutical productions can achieve accurate dosing and mixing through automated equipment to ensure uniformity of drug ingredients.

Granulation and drying:

In the granulation process, due to the large investment in research and development, the process requirements are often more stringent for originator drugs, while generics are constantly optimizing the process to reduce production costs while adopting mature technology.

Tablet compression and coating:

Tablet pressing and the subsequent coating process have a direct impact on the efficacy of the drug. The performance of the coating machines used by pharmaceutical companies directly determines the speed and effectiveness of tablet release in the body, which requires the use of high-end equipment such as advanced capsule counters and blister packaging machines. This equipment not only ensures accurate dosage but also improves packaging efficiency and ensures product stability during transportation and storage.

Differences in Production Equipment

Pharmaceutical production line: 

The entire production line tends to be more rigorous in terms of monitoring and testing systems to ensure that each step of the process meets development standards. Generic manufacturing, on the other hand, relies more on mature and efficient assembly line operations to reduce costs through mass production.

Capsule Counter: 

In capsule manufacturing, the precise dosing capabilities of the capsule counter are critical to product quality. Whether originator or generic, the accuracy of the equipment must meet international standards, but originator drugs are often equipped with more advanced testing equipment in the early stages of development to ensure high standards.

Blister Packaging Machine: 

Blister packaging is not just about external packaging; it is directly related to the stability and expiration date of the drug. The packaging process of original drugs is usually customized and optimized for blister packaging machines to ensure that the physical and chemical properties of the drugs do not change during storage and transportation; while generic drugs adopt standardized equipment, they also improve the packaging process to make the drug packaging more efficient and in line with the requirements of the international market.

In addition, the technical level of the coating machine directly affects the dissolution characteristics of the tablets and the release of the drug effect. During the R&D process of original drugs, the coating process is often fine-tuned according to the results of clinical trials, while for generic drugs, based on ensuring consistency with original drugs, appropriate process adjustments are also made according to market feedback. This continuous innovation of equipment and processes not only promotes the technological progress of the entire pharmaceutical industry but also allows consumers to benefit from higher-quality drugs.

Conclusion

From a comprehensive point of view, originator drugs and generic drugs have their own advantages: originator drugs represent the cutting edge of innovation and technology, while generic drugs, based on the inheritance of the original efficacy, reduce the cost of drugs through mature technology and large-scale production. In fact, the popularity of generic drugs has not only given more patients access to affordable treatment options but has also driven pharmaceutical companies to continuously improve their production facilities and processes.

In this process, the application of high-end equipment such as pharmaceutical production lines, capsule counters, and blister packaging machines demonstrates the continuous progress of pharmaceutical technology. The precise control ability of the blister packaging machine is directly related to the release effect of the drug in the human body, and it is these subtle links that determine the overall efficacy of the drug.

It can be said that original drugs are not necessarily superior to generics in all aspects. On the contrary, generics play an irreplaceable role in promoting market competition, lowering drug prices, improving production efficiency, and facilitating process improvement. Whether original or generic, they all work toward the same goal—to promote the development and progress of the pharmaceutical industry. The continuous innovation of pharmaceutical equipment and processes has brought us safer and more effective medicines, benefiting patients worldwide.

In the future, with the intensification of competition in the global pharmaceutical market and the continuous application of new technologies, we have reason to believe that both generic and original drugs will be processed more efficiently with the support of ever-improving pharmaceutical production lines, through equipment such as high-precision capsule counters and intelligent blister packaging machines. We have reason to believe that both generic drugs and original drugswill realize al  more efficient and stable production mode with the support of upgrading pharmaceutical production lines through high precision capsule counters, intelligent blister machines, etc., which will lead to innovation and progress of pharmaceutical technology together.